Qinlock (ripretinib)

pCPA File Number: 21850

Negotiation Status:

Concluded with an LOI

Indication(s):

Advanced gastrointestinal stromal tumor (GIST) in adult patients who have received prior treatment with imatinib, sunitinib, and regorafenib

Sponsor/Manufacturer:

Medison Pharma Canada Inc.

CDA-AMC Project Number:

PC0265-000

pCPA Engagement Letter Issued:

2022-07-12

Negotiation Process Concluded:

2023-05-12